A medical technology venture firm founded in 2013 and based in the Northeast USA makes equity investments in early stage companies developing products to accelerate the trend of precision medicine. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $15-20 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities across the world.

The firm focuses three market segments that support knowledge-generating precision medicine: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) guided and personalized minimally invasive therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An Asia-based corporate venture capital fund with a US office in California seeks to co-invest up to $3 million in Series B or C rounds. The corporate VC does not have a defined fund or budget, though typically invests a total of $10M-$20M per year, including in follow-on investments. The fund is currently seeking 2-3 new investments within the next year. The fund seeks opportunities in the U.S., Asia, Europe and Israel.

The fund has two focus areas in the life sciences; firstly, medical device technologies that have strategic relevance to the parent firm’s semiconductor business with a focus on diagnostic instrumentation and nano fabrication technology; and secondly, innovations in stem cell ancillary technology. The fund does not invest in stem cell therapies or treatments, but will look at biotech R&D innovations in the stem cell field that cultivate, study, and analyze stem cell lines. The fund is particularly interested in companies that can benefit from the parent firm’s strategic capabilities, such as companies that will need silicon nanofabrication technology. The fund is currently looking at all classes of medical device technologies, including sensor technology.

The fund typically invests in pre-revenue companies, but prefers that companies have a completed prototype and proof of concept data. The fund only invests in opportunities where the parent firm’s industry expertise is relevant, and typically provides their portfolio companies with business development and marketing support in addition to capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based early stage fund focused on angel investment and incubation in the healthcare field is currently investing from its RMB 200 M fund (USD 30 M) closed in 2015, backed by several Chinese healthcare companies. The firm’s typical investment size range from USD 1-1.5 M and is open to leading or co-investing. The firm is currently seeking opportunities in China or US-based companies with a China angle.

The firm is looking for cutting edge platform technologies in sectors including therapeutics, medical devices, and diagnostics. The firm is agnostic to therapeutic indications. In terms of development stage, the firm focuses on startup teams with some preclinical validation.

The firm is looking for strong management teams with sector expertise. The firm aims to bridge between R&D and commercialization with a focus on China-based startup teams or US companies with a China angle. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global medical technology company based in London, UK focuses on cardiovascular and neuromodulation technologies. The firm typically invests early on in the development (series A or B) stage. The firm seeks to invest in the range of $1M-$15M per company, though would pursue larger ($100M and up) deals if there were a strong rationale that would make the company an ideal, revenue-generating fit to the portfolio. The firm currently manages a growing fund, and seeks to make 1-2 larger deals and 3-4 smaller ones within the next year. The firm seeks investments globally, and has a specific focus on USA and European-based companies.

Sectors & Subsectors of Interest: 

The firm focuses on medical devices in the cardiovascular space (cardiovascular disease and associated comorbidity such as sleep apnea, etc.), specifically in technology for invasive procedures and neuromodulation areas such as stimulation for heart failure. In the cardiovascular space, the firm has interest in cardiac surgery technology, such as minimally invasive valves, tissue valves, mechanical heart valves, open-heart valves, blood circulation and transfusion technology, and blood management systems, among others. The firm is also interested in cardiac rhythmic management, such as remote monitoring technology, electro and neurostimulation, software technology, and pacemakers.

The firm will look at companies in the clinical, close to end of development stage that may be in its final round of fundraising for clinical trials. The firm is not currently focused on therapeutics or lab equipment technology, though may be open to those used to assist procedures in the cardiovascular/neurostimulation space. The firm looks at both PMA and 510K devices, as it traditionally invests in PMA devices, and is now gaining an increasing interest in 510K devices.

The firm prefers experienced management teams, and may take a board or observer seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialty pharmaceutical company headquartered in Japan focuses on pharmaceuticals, medical devices, and agro-veterinary products. The firm has strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery. The firm is currently seeking R&D collaboration and marketing alliance opportunities across Japan, Europe, US, Asia and the rest of the world.

Currently the firm is looking for innovative therapeutic products in the following areas: orthopedics with a focus on inflammation and pain, including RA/OA/arthritis pain/low-back pain; dermatology including dermatitis/acne/psoriasis; and mycology including topical and systemic treatments. The firm is also interested in peri-surgical medical devices as well as ophthalmology and niche market products.

The firm seeks to partner with publicly and privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm backed by a single HNW individual is based in California with additional offices in Israel.  The firm focuses on seed and series A investments and usually makes investments in the range of $250K-$5M. Investments may be in the form of convertible notes or straight equity, depending on the company and terms of the deal.  The firm’s nimble structure allows some flexibility in terms of capital structure, investment size etc. The firm will lead rounds as well as syndicate with other investors, and has as large network and access to additional capital.

In terms of the life sciences, the firm is interested in technology at the intersection of data and healthcare with a particular interest in algorithms for increasing efficiency/efficacy of early-stage drug discovery. The firm is also interested in medical devices and diagnostic technologies.

The firm is open to companies globally, but prefers to invest in companies located in or close to the Bay Area or Israel. The firm will work with all types of entrepreneurs, but would like to see meaningful references for novice entrepreneurs. A board seat is not required, but may be sought depending on the company and investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A seed fund founded by a China-based investment firm supports early stage companies and helps startups from the US and Europe expand successfully into the China market.  The fund is an active early stage medtech and biotech investor. The firm supports companies throughout the development process and typically invests up to $500,000 per company. The seed fund has particular success in fostering joint development initiatives between U.S. and China-based companies, and invests in companies based in the U.S., China and Europe.

The fund invests in early stage therapeutics, medical devices, diagnostics, and healthcare services and IT that may still need FDA approval and have a fast-track clinical development platform approved by the China SFDA. The firm is particularly interested in companies that have clinical development plans and interest in China. The fund is also open to lab equipment and drug development enabling technology.

The fund supports companies who have an international business model with desire to expand into the US, China, and/or Europe.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com